SCHEMBL2218016

SCHEMBL2218016

C[C@@H]1CN(c2ncc(-c3ccc(N(C)C)cc3)cc2C=O)C[C@H](C)O1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAK O14976 6/20 0.39
ALDH1A1 P00352 5/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 2/20 0.37
ATM Q13315 1/20 0.37
AOC3 Q16853 2/20 0.37
GAA P10253 3/20 0.36
MAPT P10636 2/20 0.36
RAB9A P51151 1/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2D6 P10635 1/20 0.35
HPGD P15428 1/20 0.35
PDGFRB P09619 1/20 0.34
PDGFRA P16234 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2212966 0.87 AOC3 (0.37) GAKALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2217996 0.86 GAK (0.42) GAKALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2215416 0.86 GAK (0.52) GAKALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2216042 0.85 GAK (0.41) GAKALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2215363 0.81 LRRK2 (0.40) GAKALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2212554 0.81 ERN1 (0.41) GAKALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2217666 0.81 GAK (0.37) GAKALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2214723 0.80 PIK3CA (0.45)
SCHEMBL2212992 0.80 ERN1 (0.44) GAKALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2212997 0.79 GAK (0.35) GAKALDH1A1L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178064-A1 SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL ASTRAZENECA R&D (SE) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178064-A1 SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL TBCA, TUBA1A, BROX GAK 1986/4885ALDH1A1 246/4885L3MBTL1 4446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.